Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

Clinical Infectious Diseases - Tập 63 Số 12 - Trang 1615-1618 - 2016
Ryan K. Shields1,2,3, Brian A. Potoski1,2,4, Ghady Haidar2, Binghua Hao3, Yohei Doi2, Liang Chen5, Ellen G. Press2, Barry N. Kreiswirth5, Cornelius J. Clancy2,6,3, M. Hong Nguyen1,2,3
1Antibiotic Management Program
2Department of Medicine
3XDR Pathogen Laboratory, University of Pittsburgh Medical Center
4Department of Pharmacy and Therapeutics, University of Pittsburgh
5Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark
6VA Pittsburgh Healthcare System, Pennsylvania

Tóm tắt

Từ khóa


Tài liệu tham khảo

Acycaz (Ceftazidime-avibactam). Prescribing information. Cincinnati, Ohio: Forest Pharmaceuticals, Inc, 2016.

10.1128/AAC.00548-15

Center for Disease Control and Prevention. Healthcare-associated infections (HAIs): CRE definition. Available at: https://www.cdc.gov/hai/organisms/cre/definition.html. Accessed 6 April 2016.

Centers for Disease Control and Prevention/National Healthcare Safety Network Surveillance Definitions for Specific Types of Infections (January 2016). Available at: http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf . Accessed 1 March.

10.1111/ajt.12424

10.1093/jac/dkp498

10.1053/j.ajkd.2013.02.349

10.1111/1469-0691.12697

10.1128/AAC.03894-14

10.1128/AAC.02638-15

10.1128/AAC.01165-15

10.1128/AAC.00678-15